EU Approval For Novo's Activelle
Novo Nordisk's new hormone replacement therapy product Activelle(17-beta-estradiol 1mg plus norethisterone acetate 0.5mg) has become the first product in its class to be approved and mutually-recognized by all 15 member states of the European Union. Activelle is already marketed in Sweden and will be launched in the UK, Germany and Norway later this year.
The product is a continuous-combined HRT (ie both estrogen and progestogen are continuously administered), and like other new-generation HRT products uses lower doses of hormone to minimize side effects while providing optimal efficacy in relieving the symptoms of the menopause, eg hot flushes and night sweats.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze